Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omega-3 ethylester concentrate - Pronova BioPharma

Drug Profile

Omega-3 ethylester concentrate - Pronova BioPharma

Alternative Names: Esapent; Eskim; Lotriga; Lovaza; Omacor; Seacor; TAK-085

Latest Information Update: 28 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pronova Biocare
  • Developer Ferrer; GlaxoSmithKline; Kuhnil Pharmaceutical Company; Pronova BioPharma; Reliant Pharmaceuticals; Takeda
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors; Fatty acid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia; Postmyocardial infarction
  • Phase III Cardiovascular disorders
  • Phase I Hyperlipidaemia
  • No development reported Coronary artery disease; Heart failure
  • Discontinued Atrial fibrillation; IgA nephropathy

Most Recent Events

  • 28 Mar 2019 No recent reports of development identified for clinical-Phase-Unknown development in Coronary artery disease in USA (PO)
  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 19 Jul 2016 Takeda plans the exploratory LOTUS clinical trial for Hyperlipidaemia (Adjunctive treatment) in Japan (PO) (NCT02839902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top